The startup develops fully human and canine-feline therapeutic monoclonal antibodies for human and animal health applications. By providing these licensed antibodies to pharmaceutical companies, it enhances drug development opportunities in the biopharmaceutical sector.
Funding
$8.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The discovery of therapeutic monoclonal antibodies, particularly those targeting complex membrane proteins or specific conformational epitopes, is often limited by traditional antibody library technologies. This can hinder the development of novel biologics for diseases with unmet medical needs in both human and animal health.
Solution
MabGenesis is a biopharmaceutical company providing first-in-class and best-in-class therapeutic monoclonal antibody drugs for human and animal health. The company leverages its MOURA library, a high-quality antibody library, and IMPACT, a high-efficiency monoclonal antibody isolation technology, to discover antibodies that recognize subtle structural differences in membrane proteins. MabGenesis offers research collaboration, a discovery pipeline, and technology licensing to expand new drug research and development opportunities for pharmaceutical companies.
Target Audience
The primary customers are pharmaceutical and biotechnology companies seeking novel therapeutic monoclonal antibodies for drug development in human and animal health.
Features
- MOURA library: A comprehensive antibody library for isolating fully human and canine/feline antibodies.
- IMPACT technology: A high-throughput screening platform for efficient identification of monoclonal antibodies.
- Capability to generate antibodies against difficult targets, including membrane proteins and specific conformational epitopes.
- Antibody discovery pipeline focused on autoimmune diseases, inflammatory diseases, and cancers in both humans and animals.
- Collaborative research programs to generate high-quality therapeutic monoclonal antibodies tailored to partner specifications.
- IgG conversion and functional assessment of identified antibody candidates.